Target Price | $4.25 |
Price | $3.10 |
Potential |
37.10%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Amylyx Pharmaceuticals 2025 .
The average Amylyx Pharmaceuticals target price is $4.25.
This is
37.10%
register free of charge
$8.00
158.06%
register free of charge
$3.00
3.23%
register free of charge
|
|
A rating was issued by 7 analysts: 1 Analysts recommend Amylyx Pharmaceuticals to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amylyx Pharmaceuticals stock has an average upside potential 2025 of
37.10%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 380.79 | 87.68 |
1,612.96% | 76.98% | |
EBITDA Margin | 10.48% | -353.76% |
101.16% | 3,476.99% | |
Net Margin | 12.52% | -307.10% |
101.37% | 2,553.85% |
6 Analysts have issued a sales forecast Amylyx Pharmaceuticals 2024 . The average Amylyx Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Amylyx Pharmaceuticals EBITDA forecast 2024. The average Amylyx Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2023 | 10.48% | 101.16% |
---|---|---|
2024 |
-353.76%
3,476.99%
Unlock
|
2 Amylyx Pharmaceuticals Analysts have issued a net profit forecast 2024. The average Amylyx Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.70 | -3.96 |
123.49% | 665.71% | |
P/E | negative | |
EV/Sales | negative |
2 Analysts have issued a Amylyx Pharmaceuticals forecast for earnings per share. The average Amylyx Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Amylyx Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Amylyx Pharmaceuticals...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.